Data report: Equalant II.

Mode of access: Internet.

Able to save : or, Encouragement to patient waiting.

Mode of access: Internet.

American and English corporation cases ; a collection of all corporation cases, both private and municipal (excepting railway cases), decided in the courts of last resort in the United States, England, and Canada [1883-1894] ..

Editors : Vols. 1-8, L. Lewis, jr., and J. H. Merrill.--v. 9-16, A. Hamilton.--v. 17-18, J. H. Merrill.--v. 19-20, 31-48, W. M. McKinney.--v. 21-23, J. M. Kerr and W. M. McKinney.--v. 24-30, J. C. Thomson and W. M. McKinney

Special report on diseases of cattle,

Mode of access: Internet.

Phosphorus and its compounds.

v. 1. Chemistry.--v. 2. Technology, biological functions, and applications.

A treatise on the law of wills; including also gifts causa mortis and a summary of the law of descent, distribution and administration.

Mode of access: Internet.

Trade unionism in the United States (1833-1839)

Reprinted from John R. Commons and Associates "History of Labor in the United States."

End connections of pretensioned I-beam bridges.

Mode of access: Internet.

Vibration control

Mode of access: Internet.

Patriotic addresses in America and England, from 1850 to 1885, on slavery, the Civil War, and the development of civil liberty in the United States.

Mode of access: Internet.

Who's who in Oz /

Mode of access: Internet.

Concerning some legal responsibilities in the practice of architecture and engineering and some recent changes in the contract documents.

"An edited version of the report Professional liability and responsibility, prepared in collaboration with the Subcommittee on Professional Liability and Responsibility of American Institute of Architects-Engineers Joint Council Liaison Committee."

Monograph on Leonardo da Vinci's ʻMona Lisaʻ.

The Appendix contains selections from the authorities from whom the major portion of the text of each chapter has been drawn.

Special pathology and therapeutics of the diseases of domestic animals,

Includes bibliographies.

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine

Advanced metastatic melanoma is incurable by standard treatments, but occasionally responds to immunotherapy. Recent trials using dendritic cells (DC) as a cellular adjuvant have concentrated on defined peptides as the source of antigens, and rely on foreign proteins as a source of help to generate a cell-mediated immune response. This approach limits patient accrual, because currently defined, non-mutated epitopes are restricted by a small number of human leucocyte antigens. It also fails to take advantage of mutated epitopes peculiar to the patient's own tumour, and of CD4(+) T lymphocytes as potential effectors of anti-tumour immunity. We therefore sought to determine whether a fully autologous DC vaccine is feasible, and of therapeutic benefit. Patients with American Joint Cancer Committee stage IV melanoma were treated with a fully autologous immunotherapy consisting of monocyte-derived DC, matured after culture with irradiated tumour cells. Of 19 patients enrolled into the trial, sufficient tumour was available to make treatments for 17. Of these, 12 received a complete priming phase of six cycles of either 0.9X10(6) or 5X10(6) DC/intradermal injection, at 2-weekly intervals. Where possible, treatment continued with the lower dose at 6-weekly intervals. The remaining five patients could not complete priming, due to progressive disease. Three of the 12 patients who completed priming have durable complete responses (average duration 3 5 months +), three had partial responses, and the remaining six had progressive disease (WHO criteria). Disease regression was not correlated with dose or with the development of delayed type hypersensitivity responses to intradermal challenge with irradiated, autologous tumour. However, plasma S-100B levels prior to the commencement of treatment correlated with objective clinical response (P = 0.05) and survival (log rank P < 0.001). The treatment had minimal side-effects and was well tolerated by all patients. Mature, monocyte-derived DC preparations exposed to appropriate tumour antigen sources can be reliably produced for patients with advanced metastatic melanoma, and in a subset of those patients with lower volume disease their repeated administration results in durable complete responses.